Colorectal cancer risk laboratory test from blood.
The ColonAiQ test is suitable for assessing the risk of the presence and near-future development of cancerous lesions and adenomas of the colon and rectum. The test can also be used to assess the risk of recurrence and metastasis after radical removal of colorectal cancer. The test is performed from a venous blood sample.
In the case of a high-risk result, the presence or recurrence of advanced colorectal adenoma or colorectal cancer is very likely. Colonoscopy and endoscopy are recommended at a gastroenterologist in the future.
In the case of a low-risk result, the presence or recurrence of advanced adenoma or colorectal cancer is unlikely. A low-risk result in itself cannot be considered a negative, exclusionary diagnosis. Always consult a gastroenterologist if you have a complaint.
Colorectal, i.e., colon and rectal cancers, in most cases develop from adenomas on the inner surface of the intestinal wall. Benign adenomas develop into malignant tumors in approximately 5-10 years, and if detected early, the disease has a very good chance of being cured.
The development of a malignant lesion depends on the degree of activity of certain genes. The extent of gene activity is determined by their methylation pattern, so the methylation pattern of genes is proportional to the malignant process itself.
The ColonAiQ test examines the methylation pattern of five regions of a total of 4 genes (two sections of the SEPT9 gene, one section each of the BCAT1, IKZF1 and VAV3 genes). The appearance of the hypermethylation pattern of the examined genes precedes the malignant changes of the cells in time.
It is recommended to perform the ColonAiQ test regularly, at least every 4-5 years, for everyone over the age of 50, both women and men. It is especially recommended for the examination of the elderly, those with chronic diseases, and patients unsuitable for colonoscopy, as well as for the follow-up of patients who have previously undergone colon and rectal cancer surgery.